Skip to content
ESPT
MARKETS / NYSE / Health care / Medical devices and instruments / TFX
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Teleflex Inc. TFX

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.0B
▲ 17.2% YoY
$-905.6M
▼ 1399.8% YoY
$1.4M
▼ 99.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Teleflex primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Its major manufacturing operations are located in the Czech Republic, Malaysia, Mexico and the United States. As of December 31, 2025, it employed approximately 15,500 employees, including 3,700 employees in the U.S. and 11,800 employees in 38 other countries around the world. It has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Teleflex was founded in 1943 as a manufacturer of precision mechanical push/pull controls for military aircraft. Following the divestitures of its marine business and cargo container and systems businesses in 2011, it became exclusively a medical device company.

Written from the business description in TELEFLEX INCORPORATED's annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth

USD 2.0B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.0 · Net income -0.9
1.0B2.0B-0.4B-0.8B
2008201120142017202020232025
Compound annual growth
−10.6%
−4.7%
+1.0%
+2.4%
+0.0%
+0.0%
+0.0%
+0.0%
+78.1%
+41.6%
+20.3%
+13.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −4.7% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−45 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 5.9% · Net -45.4%
10%20%-20%-40%
200820162025
ROE
FY2025 · ROE -24.5%
10%20%-10%-20%
200820162025
Three returns, three denominators.
Gross margin56.2%
Operating margin5.9%
Net margin-45.4%
EBITDAUSD 174.5M

Each USD of equity lost 24 cents this year.

Cash & shareholders

USD 360.3M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 1.4
250.0M500.0M
200820162025
Net buybacks $M Dividends $M
FY2025 · Dividends 60.3 · Net buybacks 300.0
150M300MDividendsNet buybacks
2008201120142017202020232025
Dividends paidUSD 60.3M
Net buybacksUSD 300.0M
Share of profit-39.8%
Consecutive raises·

USD 60.3M in dividends and USD 300.0M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 6.9B
EquityUSD 3.1B
CashUSD 378.6M
Gross debtUSD 2.6B
Net debtUSD 2.3B
Current ratio2.54×

Net debt stands at 72% of equity.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
TFX, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B2.01.71.72.82.82.52.62.42.11.91.81.81.71.61.51.41.41.9
Operating income $B0.10.10.30.50.60.40.40.30.40.30.30.30.2−0.10.20.20.30.2
EBITDA $B0.20.20.30.60.70.50.50.40.40.40.40.30.3−0.10.30.30.30.3
Income tax $B−0.0−0.00.00.10.10.0−0.10.00.10.00.00.00.00.00.00.00.00.0
Net income $B−0.90.10.40.40.50.30.50.20.20.20.20.20.2−0.20.30.20.30.1
Free cash flow $B0.00.20.20.30.60.30.30.40.40.40.20.20.20.10.00.10.10.1
EPS, diluted $−20.251.487.537.6810.237.099.804.293.274.985.104.043.45−4.657.924.997.593.01
Dividend / sh $1.361.361.361.361.361.361.361.361.361.361.361.361.361.361.361.361.361.34
Payout %−7911818131914314025233037−2917271844
ROE %−24.51.68.49.313.710.616.78.16.711.412.59.88.2−10.117.212.021.19.3

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. One check was skipped: EPS is not tagged before 2008. One check was skipped: revenue is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image